Machine-assisted evidence synthesisParkinson’s disease

26 August 2026 · 3 min readStrongest source: systematic review or meta-analysis

Is Parkinson's hereditary?

An old oak tree with a wide branching crown against a pale sky, a small cluster of its many leaves turned ochre.
Illustration: generated image.

In short

  • Family history is the strongest known risk factor — an odds ratio of 3.23 for a first-degree relative, ahead of constipation and pesticide exposure.
  • An odds ratio is a comparison, not a chance. Three times a small number is still a small number, and most people with an affected relative never develop Parkinson's.
  • LRRK2 G2019S, the most common single-gene cause, carries a tenfold relative risk — and a cumulative incidence of 49% by age 80. Close to a coin toss, for the strongest genetic cause known.
  • One of two common GBA mutations was found in 15% of Ashkenazi Jewish patients against 3% of controls; limited screening "can miss half the mutant alleles".
  • Testing does not resolve it. There is no treatment that changes the course of the disease to act on the result with.

This question is usually asked by someone whose parent has just been diagnosed, and it usually gets one of two answers. Either "Parkinson's is not generally inherited", which is reassuring and incomplete. Or a list of genes, which is accurate and alarming out of proportion.

The evidence supports something more specific than either.

Family history is the strongest known risk factor

A meta-analysis of risk factors for Parkinson's found that the strongest associations with later diagnosis were having a first-degree relative with Parkinson's (odds ratio 3.23) or any relative with it (4.45) — ahead of constipation, ahead of pesticide exposure, ahead of everything else it measured. Having any relative with tremor carried an odds ratio of 2.74.

So the honest headline is: yes, it runs in families more than chance would predict, and family history matters more than any environmental factor on that list.

But an odds ratio is a comparison, not a chance

This is where most articles go wrong, and it is worth being slow about.

An odds ratio of 3.23 does not mean you have a 3.23-in-something chance of anything. It means people with an affected first-degree relative were about three times as likely to be diagnosed as people without one. Three times a small number is still a small number.

Parkinson's is uncommon at the individual level. Tripling an uncommon outcome produces a still-uncommon outcome. The ratio describes the relationship; it does not describe your life. Any article that quotes a multiplier without saying what it multiplies has told you almost nothing, and it will feel like it told you a lot.

The specific genes, and what "penetrance" does to them

Two genetic findings are worth knowing because they are the ones you will encounter.

GBA. A sixteen-centre study genotyped 5,691 people with Parkinson's and 4,898 controls. Among Ashkenazi Jewish participants, one of two common GBA mutations was found in 15% of patients and 3% of controls; among non-Ashkenazi participants, 3% of patients and under 1% of controls. Full sequencing of 1,883 non-Ashkenazi patients found mutations in 7% — meaning limited screening "can miss half the mutant alleles". The odds ratio for any GBA mutation was 5.43.

LRRK2 G2019S, the most common single-gene cause of Parkinson's. A 2024 study followed 1,286 carriers and 109,154 controls. Carriers had "a 10-fold risk of developing PD versus non-carriers", rising to 27-fold for carriers who also carried a high polygenic risk score.

Ten-fold sounds close to a verdict. Then the same study reports the number that matters more: "The cumulative incidence of PD in G2019S carriers by age 80 was 49%."

Just under half. Carrying the most common monogenic cause of Parkinson's, by the age of eighty, is close to a coin toss — and that is for the strongest single genetic cause known. The gene raises risk enormously in relative terms and still leaves the outcome genuinely open.

That gap between a 10-fold risk and a 49% outcome is the whole subject in one statistic. Most genetic risk in Parkinson's is like this: real, measurable, and not destiny.

What this means if a parent has been diagnosed

Three things follow from the evidence above.

Your risk is elevated. That is what an odds ratio of 3.23 means and there is no honest way to soften it.

It remains, in absolute terms, a minority outcome. Most people with an affected first-degree relative do not develop Parkinson's.

Testing does not resolve it. Even a positive result for the strongest known variant leaves you at roughly 49% by 80 — and there is no treatment that changes the course of the disease to act on the information with. Genetic testing in Parkinson's is mostly useful for research participation and for a small number of specific situations, which is a conversation for a clinical geneticist rather than a decision to make from an article.

The reason this question feels unanswerable is that the honest answer has two halves that pull in opposite directions, and most writing picks one. Family history is the strongest risk factor there is, and most people with a family history will not get Parkinson's. Both.

Sources

  1. Systematic review or meta-analysis

    Noyce AJ, et al. Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Ann Neurol. 2012;72:893–901.

    “The strongest associations with later diagnosis of PD were found for having a first-degree or any relative with PD (odds ratio [OR], 3.23; 95% confidence interval [CI], 2.65-3.93 and OR, 4.45; 95% CI, 3.39-5.83) or any relative with tremor (OR, 2.74; 95% CI, 2.10-3.57)”
  2. Observational study

    Sidransky E, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med. 2009;361:1651–61.

    “Among Ashkenazi Jewish subjects, either mutation was found in 15% of patients and 3% of controls, and among non-Ashkenazi Jewish subjects, either mutation was found in 3% of patients and less than 1% of controls. GBA was fully sequenced for 1883 non-Ashkenazi Jewish patients, and mutations were identified in 7%, showing that limited mutation screening can miss half the mutant alleles. The odds ratio for any GBA mutation in patients versus controls was 5.43 across centers.”
  3. Observational study

    Kmiecik MJ, et al. Genetic analysis and natural history of Parkinson's disease due to the LRRK2 G2019S variant. Brain. 2024;147:1996–2008.

    “The cumulative incidence of PD in G2019S carriers by age 80 was 49%. G2019S carriers had a 10-fold risk of developing PD versus non-carriers. This rose to a 27-fold risk in G2019S carriers with a PD polygenic risk score in the top 25% versus non-carriers in the bottom 25%.”